Results 191 to 200 of about 7,548 (263)

Initiation or switch to insulin degludec/insulin aspart in adults with type 2 diabetes in India: Results from a prospective, non-interventional, real-world study. [PDF]

J Family Med Prim Care
Baruah MP, Aneja P, Pitale S, Bhograj A, Agrawala RK, Aggarwal A, Mahadev PG, Madhavdas DC, Shah S, John M, Pathan MKA, Revanna M, Chandrappa M, Singh KP.   +13 more
europepmc   +1 more source

Combined intake of caffeine and low‐dose glucose to reduce exercise‐related hypoglycaemia in individuals with type 1 diabetes on ultra‐long‐acting insulin degludec: A randomized, controlled, double‐blind, cross‐over trial [PDF]

Tobias Kühne, Esmé Wallace, David Herzig, Simon Helleputte, Sam N. Scott, Jordan Pickles, Andreas Melmer, Christoph Stettler   +7 more
openalex   +1 more source

This Trial is Conducted Globally. The Aim of This Trial is to Compare the Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification.

Novo Nordisk
openalex   +1 more source

Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes

Novo Nordisk
openalex   +1 more source

Comparison of efficacy and safety of insulin degludec/liraglutide and insulin glargine U-100/lixisenatide in individuals with type 2 diabetes mellitus using professional continuous glucose monitoring. [PDF]

J Diabetes Investig
Kawaguchi Y, Hajika Y, Rinka M, Masumoto K, Sawa J, Hamazaki K, Kumeda Y.   +6 more
europepmc   +1 more source

Efficacy and Safety of Insulin Degludec/Insulin Aspart versus Biphasic Insulin Aspart 30 in Patients with Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials. [PDF]

Iran J Public Health
Niu YL, Zhang Y, Song ZY, Zhao CZ, Luo Y, Wang Y, Yuan J.   +6 more
europepmc   +1 more source

Safety and glycemic control with insulin degludec use in clinical practice: results from a 3-year Japanese post-marketing surveillance study. [PDF]

Diabetol Int
Murata T, Husemoen LLN, Nemoto S, Matsuhisa M.   +3 more
europepmc   +1 more source

Interactions between kidney disease and diabetes: dangerous liaisons [PDF]

core   +1 more source

Available datapackage for study 'A Randomised, Cross-over, Open-label, Multi-centre Trial Comparing the Effect of Insulin Degludec and Insulin Glargine 100U/mL, With or Without OADs in Subjects With Type 2 Diabetes Using Flash Glucose Monitoring'

Novo Nordisk
openalex   +1 more source